NKGen Biotech, Inc. (NKGN)
Fuera de horario:
NKGen Biotech, Inc.
3001 Daimler Street
Santa Ana, CA 92705
United States
949-396-6830
https://nkgenbiotech.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 63
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Paul Y. Song M.D. | CEO & Chairman | 650k | N/D | 1966 |
| Dr. Yong Man Kim Ph.D. | Chief Scientific Officer | 60k | N/D | 1965 |
| Mr. James A. Graf | Interim Chief Financial Officer | N/D | N/D | 1965 |
| Mr. Pierre Gagnon | Chief Operating Officer | N/D | N/D | 1972 |
| Ms. Yoonmi Kang | Vice President of Technical Operations | N/D | N/D | N/D |
| Ms. Denise A. Chua CLS, MBA, MT (ASCP) | Vice President of Investor Relations & Corporate Communications | N/D | N/D | N/D |
| Ms. Irene Chang | Vice President of Human Resources | N/D | N/D | N/D |
| Mr. Sangwoo Park | Executive Director | 576k | N/D | 1970 |
| Mr. Ryan Park C.F.A. | SVP of Financial Planning & Analysis and Corporate Strategy | N/D | N/D | N/D |
Descripción
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California. NKGen Biotech, Inc. operates as a subsidiary of NKMAX Co., Ltd.
Gestión corporativa
La calificación ISS Governance QuickScore de NKGen Biotech, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
